Next Investors logo grey

Creso Pharma signs first letter of intent for import and sale of cannabis products in Australia


Published 03-FEB-2017 11:50 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma (ASX: CPH) has announced that it has expanded its Australian presence, signing its first Australian letter of intent with Western Australian-based pharmacy, Health House International, for the import and sale of cannabis products in the Australian market.

CPH has established itself as a leader in cannabidiol (CBD) innovation and the group develops cannabis and hemp derived therapeutic grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health.

Consequently, this agreement is a significant development for the company as it opens up an additional revenue stream and expands its presence in a familiar market where there is political support for the use of cannabis related products in treating medical conditions.

Next Investors Image

Further demonstrates the benefits of CPH’s vertically integrated model

Under the terms of the letter of intent, Health House International will initially conduct a trial importation of cannabis oil products from Canadian-based third-parties introduced by Creso.

Following success of the trial in accordance with all Australian Laws and regulations, the parties have agreed to enter into an agreement for an initial two-year term (with an option of extension), subject to Health House International purchasing and importing the agreed minimum quantities of product. Creso will act as the facilitator for the import of the products into Australia and earn a facilitation fee on each Health House International import.

Once imported, Health House International will look to distribute products to Australian patients that can buy medical cannabis under the new Australian laws via its West Australian-based pharmacy and through the regulated national distribution chains.

Health House International will also look to supply products to patients enrolled in clinical trial programs initiated by Medical Cannabis Research Australia or other research institutions.

Government support augurs well for the future

CPH has been quick to respond to this new market opportunity as the legalisation of medical cannabis by the Federal Government in Australia was only ratified last year.

However, CPH is still in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.

The move follows the legalisation of medical cannabis by the Federal Government in Australia last year and a supportive statement by the Prime Minister to initiate Medical Cannabis imports alongside building the local Medical Cannabis industry.

Under the federal scheme, patients with a valid prescription can possess and use medicinal cannabis products provided the supply has been authorised under the Therapeutic Goods Act and relevant state and territory legislation. The changes put medical cannabis in the same category as restricted medicinal drugs such as morphine.

The Australian medical cannabis market represents an attractive opportunity for Creso.

Creso Pharma Chairman and Co-Founder Boaz Wachtel said, “We look forward to working with Health House International to supply these Cannabis oils products for human health.”

Health House International Director and Perth based pharmacist Paul Mavor said, “We are excited to be working with Creso and importing some of the first sophisticated Medical Cannabis products into Australia at a time when cannabis based medicine is being researched for a few conditions where there are no other treatment options”.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.